Boschert S - Women with osteoporosis treated with teriparatide often gain lumbar spine bone mineral density and lower their risk of vertebral fracture, even if they lose hip bone mineral density. Methods
An analyses of data on women with a history of vertebral fractures randomized to take 20 or 40 mcg/day of teriparatide or placebo
The women self-administered the treatments sc and also received daily supplements of 1,000 mg of calcium and 400–1,200 IU of vitamin D
The risk of vertebral fracture was calculated for women on placebo and for women in 4 subgroups of teriparatide therapy based on changes in femoral neck BMD 1 year from baseline
Results
35% of pts gained more than 4% in femoral neck BMD vs placebo
Women also showed reductions in vertebral fracture risk on teriparatide therapy vs placebo regardless of changes in femoral neck BMD at 1 year
Lumbar spine BMD increased significantly more in women on teriparatide, vs placebo, regardless of changes in femoral neck density
Lumbar spine density increased by 3% or greater in 78%–92% of women on teriparatide in the four femoral neck subgroups
See all
